Alessandro D. Santin, MD

Professor of Obstetrics, Gynecology, and Reproductive Sciences; Clinical Research Program Leader, Gynecologic Oncology Program, Yale Cancer Center

Clinical Interests

  • Medical Oncology

Patient Care

Accepts new patients? Yes
Patient Type: Adult; Child
Referrals: From patients or physicians

Patient Care Organizations

Cancer Center, Yale: Gynecologic Oncology Program

Obstetrics, Gynecology & Reproductive Sciences: Discovery to Cure | Gynecologic Oncology | Ovarian Cancer Program, Early Detection

Yale Medical Group

Clinical Trials

Conditions Study Title
Ovary In Vitro Treatment of Chemotherapy Resistant Human Ovarian Cancer by Administration of CPE
Corpus Uteri Randomized Phase II Evaluation of Carboplatin/Paclitaxel with and without Trastuzumab (Herceptin) in HER2/neu+ Patients with Advanced/Recurrent Uterine Serous Papillary Carcinoma
Ovary CPE Peptide-based Nanoparticles for the Diagnosis and Treatment of Chemotherapy-resistant Ovarian Cancer
Other Female Genital Expression of Inhibitory B-7 Family Molecules in the Tumor Microenvironment and Peripheral Blood of Gynecologic Cancer Patients
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician's Choice of Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum
Corpus Uteri Integrated Genomic Analysis of Racial Disparities in Biologically Aggressive Endometrial Carcinoma in African American and Caucasian Women
A phase II evaluation of Afatinib, an irreversible human epidermal growth factor receptor 2 (Her2/neu) tyrosine kinase inhibitor, in patients with persistent or recurrent HER2-positive uterine serous carcinoma
A Phase II Evaluation of Nivolumab, a Fully Human Antibody against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer

Edit this profile